EMEA-002786-PIP01-20

Table of contents

Key facts

Active substance
Icosasodium{26-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-14,14-bis{[(3-{6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy)]methyl}-8,12,19-trioxo-16-oxa-7,13,20-triazahexacosyl}2′-O-(2-methoxyethyl...
Therapeutic area
Cardiovascular diseases
Decision number
P/0245/2020
PIP number
EMEA-002786-PIP01-20
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of cardiovascular events due to atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Phone: +41 61 324 1111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating